Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy
Jieping Lei(Chinese Academy of Medical Sciences & Peking Union Medical College), Veli‐Matti Kosma(University of Eastern Finland), Peter A. Fasching(Universitätsklinikum Erlangen), Annika Lindblom(Karolinska University Hospital), Sajjad Rafiq(University Hospital Southampton NHS Foundation Trust), Joe Dennis(University of Cambridge), Ute Hamann(German Cancer Research Center), Georgia Chenevix‐Trench(QIMR Berghofer Medical Research Institute), Arif B. Ekici(University Medical Center Groningen), Kristiina Aittomäki(Helsinki University Hospital), Irene L. Andrulis(University of Toronto), Sabine Behrens(German Cancer Research Center), Per Hall(Karolinska Institutet), Silje Nord(Oslo University Hospital), Robert Luben(University of Cambridge), Heli Nevanlinna(University of Helsinki), Carl Blomqvist(University of Helsinki), Agnes Jager(Erasmus MC Cancer Institute), Celine M. Vachon(Leiden University Medical Center), Diana Torres(German Cancer Research Center), Sandrine Tchatchou(Mount Sinai Hospital), Maartje J. Hooning(Erasmus MC Cancer Institute), Petra Seibold(German Cancer Research Center), Mitul Shah(University of Cambridge), Montserrat García‐Closas(Institute of Cancer Research), Anja Rudolph(Institut für Qualität im Management (Germany)), Diether Lambrechts(VIB-KU Leuven Center for Cancer Biology), Hans-Ulrich Ulmer(Klinikum Mittelbaden), Paul D.P. Pharoah(Cedars-Sinai Medical Center), Janet E. Olson(Cornell University), Julia A. Knight, Taru Muranen(Karolinska Institutet), Qin Wang(University of Cambridge), Vessela N. Kristensen(Oslo University Hospital), Kirsten B. Moysich(Roswell Park Comprehensive Cancer Center), Matthias W. Beckmann, Emily Hallberg(University of Kansas Medical Center), Anne‐Lise Børresen‐Dale(Oslo University Hospital), Gord Glendon, Madeleine MA Tilanus-Linthorst(Erasmus MC Cancer Institute), Thomas Rüdiger(University of Würzburg), Fergus J. Couch(Mayo Clinic), Ursula Eilber(University of Helsinki), Manjeet K. Bolla(University of Cambridge), Lothar Haeberle(Friedrich-Alexander-Universität Erlangen-Nürnberg), Grethe I.G. Alnæs(Oslo University Hospital), Sara Margolin(University of Copenhagen), Ellen L. Goode(Mayo Clinic in Arizona)
Cited by 24
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k